Wikiwand AI

ICI-118,551

Chemical compound From Wikipedia, the free encyclopedia

ICI-118,551 is a selective β2 adrenergic receptor (adrenoreceptor) antagonist or beta blocker.[1][2] ICI binds to the β2 subtype with at least 100 times greater affinity than β1 or β3, the two other known subtypes of the beta adrenoceptor.[3][4] The compound was developed by Imperial Chemical Industries, which was acquired by AkzoNobel in 2008.

Quick facts Names, Identifiers ...
ICI-118,551
Names
IUPAC name
3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
EC Number
  • 998-334-3
MeSH ICI+118551
UNII
  • InChI=1S/C17H27NO2/c1-11(2)18-13(4)16(19)10-20-17-9-8-12(3)14-6-5-7-15(14)17/h8-9,11,13,16,18-19H,5-7,10H2,1-4H3
    Key: VFIDUCMKNJIJTO-UHFFFAOYSA-N
  • CC1=C2CCCC2=C(C=C1)OCC(C(C)NC(C)C)O
Properties
C17H27NO2
Molar mass 277.402 g/mol
Hazards
GHS labelling:
GHS07: Exclamation mark
Warning
H315, H319, H335
P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, P501
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X markN verify (what is checkYX markN ?)
Close

ICI-118,551 has no known therapeutic use in humans although it has been used widely in research to understand the action of the β2 adrenergic receptor, as few other specific antagonists for this receptor are known.[5] ICI-118,551 has been used in pre-clinical studies using murine models.[6][7][8] When dissolved in saline, the compound crosses the blood–brain barrier. Common systemic doses used in rodent research are 0.5 or 1 mg/kg although efficacy has been demonstrated at doses as low as 0.0001 mg/kg (100 ng/kg) in rhesus monkeys.[9] Doses up to 20 mg/kg have been used without toxicity. At room temperature in saline, the ICI 118,551 hydrochloride is soluble to at least 2.5 mg/mL.

References

Related Articles

Timelines

Top Qs

Fact Checks